Brief: NGM Bio Initiates Phase 2 Study Of NGM621 In AMD Patients
27/07/2020 14:31
July 27 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES INITIATION OF PHASE 2 CATALINA STUDY OF
NGM621
IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA) SECONDARY TO
AGE-RELATED MACULAR DEGENERATION (AMD)
Source text for Eikon: ID:nGNX2LGgQD
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors